514 related articles for article (PubMed ID: 34347945)
1. Activated Peripheral Blood B Cells in Rheumatoid Arthritis and Their Relationship to Anti-Tumor Necrosis Factor Treatment and Response: A Randomized Clinical Trial of the Effects of Anti-Tumor Necrosis Factor on B Cells.
Meednu N; Barnard J; Callahan K; Coca A; Marston B; Thiele R; Tabechian D; Bolster M; Curtis J; Mackay M; Graf J; Keating R; Smith E; Boyle K; Keyes-Elstein L; Welch B; Goldmuntz E; Anolik JH
Arthritis Rheumatol; 2022 Feb; 74(2):200-211. PubMed ID: 34347945
[TBL] [Abstract][Full Text] [Related]
2. Response to Biologic Drugs in Patients With Rheumatoid Arthritis and Antidrug Antibodies.
Bitoun S; Hässler S; Ternant D; Szely N; Gleizes A; Richez C; Soubrier M; Avouac J; Brocq O; Sellam J; de Vries N; Huizinga TWJ; Jury EC; Manson JJ; Mauri C; Matucci A; Hacein Bey Abina S; Mulleman D; Pallardy M; Broët P; Mariette X;
JAMA Netw Open; 2023 Jul; 6(7):e2323098. PubMed ID: 37436748
[TBL] [Abstract][Full Text] [Related]
3. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
[TBL] [Abstract][Full Text] [Related]
4. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
[TBL] [Abstract][Full Text] [Related]
5. Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor.
Kobie JJ; Zheng B; Bryk P; Barnes M; Ritchlin CT; Tabechian DA; Anandarajah AP; Looney RJ; Thiele RG; Anolik JH; Coca A; Wei C; Rosenberg AF; Feng C; Treanor JJ; Lee FE; Sanz I
Arthritis Res Ther; 2011; 13(6):R209. PubMed ID: 22177419
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and retention rate of adalimumab in rheumatoid arthritis and psoriatic arthritis patients after first-line etanercept failure: the FEARLESS cohort.
Favalli EG; Becciolini A; Carletto A; Conti F; Amato G; Fusaro E; Quartuccio L; Egan CG; Lo Monaco A; Benucci M; Salaffi F; Semeraro A; Parisi S; Ceccarelli F; Piazza I; Foti R
Rheumatol Int; 2020 Feb; 40(2):263-272. PubMed ID: 31435754
[TBL] [Abstract][Full Text] [Related]
7. Anti-TNF-α effects on anemia in rheumatoid and psoriatic arthritis.
Corrado A; Di Bello V; d'Onofrio F; Maruotti N; Cantatore FP
Int J Immunopathol Pharmacol; 2017 Sep; 30(3):302-307. PubMed ID: 28604144
[TBL] [Abstract][Full Text] [Related]
8. Cutting edge: anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks.
Anolik JH; Ravikumar R; Barnard J; Owen T; Almudevar A; Milner EC; Miller CH; Dutcher PO; Hadley JA; Sanz I
J Immunol; 2008 Jan; 180(2):688-92. PubMed ID: 18178805
[TBL] [Abstract][Full Text] [Related]
9. Tumor Necrosis Factor (TNF) blocking agents are associated with lower risk for Alzheimer's disease in patients with rheumatoid arthritis and psoriasis.
Zhou M; Xu R; Kaelber DC; Gurney ME
PLoS One; 2020; 15(3):e0229819. PubMed ID: 32203525
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
Weisman MH; Moreland LW; Furst DE; Weinblatt ME; Keystone EC; Paulus HE; Teoh LS; Velagapudi RB; Noertersheuser PA; Granneman GR; Fischkoff SA; Chartash EK
Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493
[TBL] [Abstract][Full Text] [Related]
11. Retention rates of adalimumab, etanercept and infliximab as first-line biotherapy agent for rheumatoid arthritis patients in daily practice - Auvergne experience.
Soubrier M; Pereira B; Frayssac T; Fan A; Couderc M; Malochet-Guinamand S; Mathieu S; Tatar Z; Tournadre A; Dubost JJ
Int J Rheum Dis; 2018 Nov; 21(11):1924-1932. PubMed ID: 28901727
[TBL] [Abstract][Full Text] [Related]
12. Satisfaction with Subcutaneous Golimumab and its Auto-Injector among Rheumatoid Arthritis Patients with Inadequate Response to Adalimumab or Etanercept.
Dehoratius RJ; Brent LH; Curtis JR; Ellis LA; Tang KL
Patient; 2018 Jun; 11(3):361-369. PubMed ID: 29427176
[TBL] [Abstract][Full Text] [Related]
13. Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study.
Smolen JS; Kay J; Matteson EL; Landewé R; Hsia EC; Xu S; Zhou Y; Doyle MK
Ann Rheum Dis; 2014 Oct; 73(10):1811-8. PubMed ID: 23897769
[TBL] [Abstract][Full Text] [Related]
14. Validation of a Bioassay for Predicting Response to Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis.
Ho CH; Silva AA; Giles JT; Bathon JM; Solomon DH; Liao KP; Ho IC
Arthritis Rheumatol; 2021 Jun; 73(6):1086-1087. PubMed ID: 33426780
[No Abstract] [Full Text] [Related]
15. Synovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: a clue to interpret different chances of relapse after clinical remission?
Alivernini S; Tolusso B; Petricca L; Bui L; Di Sante G; Peluso G; Benvenuto R; Fedele AL; Federico F; Ferraccioli G; Gremese E
Ann Rheum Dis; 2017 Jul; 76(7):1228-1236. PubMed ID: 28119289
[TBL] [Abstract][Full Text] [Related]
16. Infliximab efficacy in rheumatoid arthritis after an inadequate response to etanercept or adalimumab: results of a target-driven active switch study.
Fleischmann R; Goldman JA; Leirisalo-Repo M; Zanetakis E; El-Kadi H; Kellner H; Bolce R; DeHoratius R; Wang J; Decktor D
Curr Med Res Opin; 2014 Nov; 30(11):2139-49. PubMed ID: 25050591
[TBL] [Abstract][Full Text] [Related]
17. Multiomics and Machine Learning Accurately Predict Clinical Response to Adalimumab and Etanercept Therapy in Patients With Rheumatoid Arthritis.
Tao W; Concepcion AN; Vianen M; Marijnissen ACA; Lafeber FPGJ; Radstake TRDJ; Pandit A
Arthritis Rheumatol; 2021 Feb; 73(2):212-222. PubMed ID: 32909363
[TBL] [Abstract][Full Text] [Related]
18. Baseline CXCL10 and CXCL13 levels are predictive biomarkers for tumor necrosis factor inhibitor therapy in patients with moderate to severe rheumatoid arthritis: a pilot, prospective study.
Han BK; Kuzin I; Gaughan JP; Olsen NJ; Bottaro A
Arthritis Res Ther; 2016 Apr; 18():93. PubMed ID: 27102921
[TBL] [Abstract][Full Text] [Related]
19. The impact of conventional DMARD and biological therapies on CD4+ cell subsets in rheumatoid arthritis: a follow-up study.
Szalay B; Vásárhelyi B; Cseh A; Tulassay T; Deák M; Kovács L; Balog A
Clin Rheumatol; 2014 Feb; 33(2):175-85. PubMed ID: 23934385
[TBL] [Abstract][Full Text] [Related]
20. The immunomodulatory effects of TNF-α inhibitors on human Th17 cells via RORγt histone acetylation.
Lin YC; Lin YC; Wu CC; Huang MY; Tsai WC; Hung CH; Kuo PL
Oncotarget; 2017 Jan; 8(5):7559-7571. PubMed ID: 27926504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
